TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2866.
Locate Jan Aushadhi KendraClinical Overview
Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, usually divided twice daily, with or without meals. Taper slowly when discontinuing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Extrapyramidal symptoms (dystonia, rigidity, tremor, akathisia), drowsiness, dizziness, blurred vision, dry mouth. Rare/Severe: Tardive dyskinesia, neuroleptic malignant syndrome, and agranulocytosis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Boxed warning for dementia psychosis mortality. High risk of acute dystonic reactions and parkinsonism; anticholinergic anti-parkinsonian agents (trihexyphenidyl) are frequently co-prescribed. Contraindicated in bone marrow depression and pre-existing liver damage.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Chlordiazepoxide 10mg + Trifluoperazine 1mg Tablets
Chlordiazepoxide and Trifluoperazine combines an anxiolytic benzodiazepine with a high-potency phenothiazine antipsychotic. Trifluoperazine blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, subduing agitation and delusional thinking, while chlordiazepoxide modulates GABAA receptors to control anxiety and somatic tension. Indicated for anxiety states complicated by somatic obsessions, severe agitation, or mild psychotic symptoms.
Trihexyphenidyl Hydrochloride Tablets 2mg (Benzhexol Hydrochloride Tablets 2mg)
Trihexyphenidyl Hydrochloride (Benzhexol) is a synthetic tertiary amine centrally acting anticholinergic (antimuscarinic) agent on the WHO Model List of Essential Medicines. It competitively antagonizes muscarinic acetylcholine receptors (M1) in the corpus striatum, restoring balance between dopamine deficiency and cholinergic excess. Indicated for adjunctive treatment of Parkinson's disease (particularly for reducing resting tremor and rigidity) and prevention/treatment of drug-induced extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism) caused by neuroleptics.
Risperidone 2mg Trihexyphenidyl 2 mg Tablets (mouth Dissolving )
Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.
Risperidone 3mg Trihexyphenidyl 2 mg Tablets
Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.